Write a Comment
7 Comments
it's quite a promising drug. i stongly suggest clinical trials should include sub-saharan africa to take care of racial diferences.
These guys obviously have been sitting on a superior drug til the TDF patent nears expiration, while continually increasing the price of high toxicity Viread. Asking my doc about switching from Truvada to Epzicom.
i wonder if it would continue to be efficacious against hbv
HIV can infect any cell in the body that contains CD4 receptors, not just lymphocytes. Does the GS7340 cross the blood/brain barrier. Has viral load been measured in CSF and Seminal Fluid? If the drug only works inside of lymphocytes, will it be similiar to taking only two drugs for the rest of the body?
Meant free access for we who took Truvada last 8 years and told it was not toxic to kidneys a rebate for 2 years worth of the new stuff at 15k a year, a study on kidney toxicity was not really too costly was it? Et tu Gilead alas..still time to make good, for delaying this for dollars and no sense- and get out the hep c med and study it on co-infected folks, we are dying (literally) for that medication from Pharmasset for type 2-3 w.o. interferon is desperately needed by co-infected..
Great and scary all at once-the week after they announce why Tenofovir had to be forced to linger in the blood, which had the "unfortunate" side effect of irreversibly damaging "Some" patients tubules in their kidneys, they SUDDENLY realized that not only was their patent up, but EUREKA, that could make this better version--after the patent expires, kidney damage from UCSF/VA? Nice motivational move-.been through hell thinking kidneys damaged-proteinurea (diabetes?controlled)-free access today?
TonyDewitt
So when will they stop making Viread & start making 7340?
November 15, 2012 • Newark, NJ